{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:59:20Z","timestamp":1790258360804,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12801-y","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:03:04Z","timestamp":1790254984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics"],"prefix":"10.1007","volume":"53","author":[{"given":"Derya","family":"TOPUZ ATA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-711X","authenticated-orcid":false,"given":"An\u0131l","family":"ATA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Tuba","family":"ODACI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"12801_CR1","doi-asserted-by":"publisher","first-page":"1573618","DOI":"10.3389\/fmolb.2025.1573618","volume":"12","author":"CK Bhusal","year":"2025","unstructured":"Bhusal CK, Sinha S, Kaur D, Sehgal R (2025) Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies. Front Mol Biosci 12:1573618. https:\/\/doi.org\/10.3389\/fmolb.2025.1573618","journal-title":"Front Mol Biosci"},{"key":"12801_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/ph18081182","volume":"18","author":"A Augusto","year":"2025","unstructured":"Augusto A, Costa I, Concei\u00e7\u00e3o J, Cristiano ML (2025) Targeting trypanothione synthetase and trypanothione reductase: development of common inhibitors to tackle trypanosomatid disease. Pharmaceuticals 18:1182. https:\/\/doi.org\/10.3390\/ph18081182","journal-title":"Pharmaceuticals"},{"key":"12801_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-025-00663-w","volume":"11","author":"M Pareyn","year":"2025","unstructured":"Pareyn M, Van Bocxlaer K, Croft SL et al (2025) The leishmaniases. Nat Rev Dis Primers 11:1. https:\/\/doi.org\/10.1038\/s41572-025-00663-w","journal-title":"Nat Rev Dis Primers"},{"key":"12801_CR4","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.3390\/biomedicines13123008","volume":"13","author":"RM de Souza","year":"2025","unstructured":"de Souza RM, Tuon FF, Lindoso JAL et al (2025) Cutaneous and mucocutaneous leishmaniasis: perspectives on immunity, virulence, and treatment. Biomedicines 13:3008. https:\/\/doi.org\/10.3390\/biomedicines13123008","journal-title":"Biomedicines"},{"key":"12801_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1017\/S0031182025101522","volume":"153","author":"D Topuz Ata","year":"2026","unstructured":"Topuz Ata D, Ata A (2026) Leishmaniasis vaccine research: current status and new directions. Parasitology 153:366\u2013377. https:\/\/doi.org\/10.1017\/S0031182025101522","journal-title":"Parasitology"},{"key":"12801_CR6","doi-asserted-by":"publisher","first-page":"1001973","DOI":"10.3389\/fcimb.2023.1001973","volume":"13","author":"M Kamran","year":"2023","unstructured":"Kamran M, Bhattacharjee R, Das S, Mukherjee S, Ali N (2023) The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: perception and future perspective. Front Cell Infect Microbiol 13:1001973. https:\/\/doi.org\/10.3389\/fcimb.2023.1001973","journal-title":"Front Cell Infect Microbiol"},{"key":"12801_CR7","doi-asserted-by":"publisher","first-page":"1718438","DOI":"10.3389\/fphar.2025.1718438","volume":"2","author":"K Kalesh","year":"2025","unstructured":"Kalesh K, Barbosa EG, Jord\u00e3o AK (2025) Drug discovery for leishmaniasis and Chagas disease: compound design and therapeutic strategies. Front Pharmacol 2:1718438. https:\/\/doi.org\/10.3389\/fphar.2025.1718438","journal-title":"Front Pharmacol"},{"key":"12801_CR8","doi-asserted-by":"publisher","first-page":"e00477","DOI":"10.1128\/mbio.00477-24","volume":"15","author":"M Queffeulou","year":"2024","unstructured":"Queffeulou M, Leprohon P, Fernandez-Prada C, Ouellette M, Mej\u00eda-Jaramillo AM (2024) CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum. mBio 15:e00477\u2013e00424. https:\/\/doi.org\/10.1128\/mbio.00477-24","journal-title":"mBio"},{"key":"12801_CR9","doi-asserted-by":"publisher","first-page":"e85605","DOI":"10.7554\/eLife.85605","volume":"12","author":"M Engstler","year":"2023","unstructured":"Engstler M, Beneke T (2023) Gene editing and scalable functional genomic screening in Leishmania species using the CRISPR\/Cas9 cytosine base editor toolbox LeishBASEedit. eLife 12:e85605. https:\/\/doi.org\/10.7554\/eLife.85605","journal-title":"eLife"},{"key":"12801_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13321-024-00929-7","volume":"16","author":"E Harigua-Souiai","year":"2024","unstructured":"Harigua-Souiai E, Zine H, El Messaoudi MD et al (2024) cidalsDB: an AI-empowered platform for anti-pathogen therapeutics research. J Cheminform 16:134. https:\/\/doi.org\/10.1186\/s13321-024-00929-7","journal-title":"J Cheminform"},{"key":"12801_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12911-025-03041-4","volume":"25","author":"S Nalband","year":"2025","unstructured":"Nalband S, Chouksey A, Bhandari S et al (2025) Ensemble techniques for predictive modeling of leishmanial activity via molecular fingerprints. BMC Med Inf Decis Mak 25:378. https:\/\/doi.org\/10.1186\/s12911-025-03041-4","journal-title":"BMC Med Inf Decis Mak"},{"key":"12801_CR12","doi-asserted-by":"publisher","first-page":"1450908","DOI":"10.3389\/fitd.2025.1450908","volume":"6","author":"M Tamir","year":"2025","unstructured":"Tamir M, Birke Teketelew B, Berta DM et al (2025) Review of host-directed immunotherapy and candidate agents against leishmaniasis. Front Trop Dis 6:1450908. https:\/\/doi.org\/10.3389\/fitd.2025.1450908","journal-title":"Front Trop Dis"},{"key":"12801_CR13","doi-asserted-by":"publisher","first-page":"118276","DOI":"10.1016\/j.bmc.2025.118276","volume":"128","author":"M Shahid","year":"2025","unstructured":"Shahid M, Ahmad S, Ahmad M et al (2025) Targeting MAP kinase for inhibiting Leishmania promastigote and amastigote stages by L-alanine-derived molecules and their anticancer potential against PANC-1 cell lines. Bioorg Med Chem 128:118276. https:\/\/doi.org\/10.1016\/j.bmc.2025.118276","journal-title":"Bioorg Med Chem"},{"key":"12801_CR14","doi-asserted-by":"publisher","first-page":"10908","DOI":"10.3390\/ijms252010908","volume":"25","author":"Y Ning","year":"2024","unstructured":"Ning Y, Basu S, Hsu FF, Feng M, Wang MZ, Zhang K (2024) Molecular characterization of sterol C4-methyl oxidase in Leishmania major. Int J Mol Sci 25:10908. https:\/\/doi.org\/10.3390\/ijms252010908","journal-title":"Int J Mol Sci"},{"key":"12801_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17460441.2025.2450787","volume":"20","author":"GP Dos Santos","year":"2025","unstructured":"Dos Santos GP, Coelho AC, Reim\u00e3o JQ (2025) The latest progress in assay development in leishmaniasis drug discovery: a review of the available papers on PubMed from the past year. Expert Opin Drug Discov 20:177\u2013192. https:\/\/doi.org\/10.1080\/17460441.2025.2450787","journal-title":"Expert Opin Drug Discov"},{"key":"12801_CR16","doi-asserted-by":"publisher","first-page":"109753","DOI":"10.1016\/j.compbiomed.2025.109753","volume":"188","author":"A Nawaz","year":"2025","unstructured":"Nawaz A, Rai GP, Singh K, Shanker A, Ali V (2025) Computational approaches and experimental investigation for identification of potential inhibitors targeting cysteine synthase in Leishmania donovani. Comput Biol Med 188:109753. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109753","journal-title":"Comput Biol Med"},{"key":"12801_CR17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s11033-026-12285-w","volume":"53","author":"A Ata","year":"2026","unstructured":"Ata A, Topuz Ata D (2026) A comprehensive review of CRISPR-Cas9-mediated genome editing in Leishmania strains: methodologies, applications, challenges and future directions. Mol Biol Rep 53:1122. https:\/\/doi.org\/10.1007\/s11033-026-12285-w","journal-title":"Mol Biol Rep"},{"key":"12801_CR18","doi-asserted-by":"publisher","first-page":"51271","DOI":"10.1021\/acsomega.4c07994","volume":"9","author":"ESA Santos","year":"2024","unstructured":"Santos ESA, Oliveira GM, Silva J\u00fanior EN et al (2024) Deep multitask learning-driven discovery of new compounds targeting Leishmania infantum. ACS Omega 9:51271\u201351284. https:\/\/doi.org\/10.1021\/acsomega.4c07994","journal-title":"ACS Omega"},{"key":"12801_CR19","doi-asserted-by":"publisher","first-page":"653670","DOI":"10.3389\/fcimb.2021.653670","volume":"11","author":"ECA Hor\u00e1cio","year":"2021","unstructured":"Hor\u00e1cio ECA, Hickson J, Murta SMF, Ruiz JC, Nahum LA (2021) Perspectives from systems biology to improve knowledge of Leishmania drug resistance. Front Cell Infect Microbiol 11:653670. https:\/\/doi.org\/10.3389\/fcimb.2021.653670","journal-title":"Front Cell Infect Microbiol"},{"key":"12801_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/pathogens12010039","volume":"12","author":"AA Rabaan","year":"2023","unstructured":"Rabaan AA, Al-Malki AL, Al-Habib A et al (2023) Omics approaches in drug development against leishmaniasis: current scenario and future prospects. Pathogens 12:39. https:\/\/doi.org\/10.3390\/pathogens12010039","journal-title":"Pathogens"},{"key":"12801_CR21","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.ijpddr.2024.100538","volume":"25","author":"LG Azevedo","year":"2024","unstructured":"Azevedo LG, Soares PA, Ferreira TR et al (2024) High-throughput prioritization of target proteins for development of new antileishmanial compounds. Int J Parasitol Drugs Drug Resist 25:100538. https:\/\/doi.org\/10.1016\/j.ijpddr.2024.100538","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"12801_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s42003-025-08331-1","volume":"8","author":"LN Gonzalez-Garcia","year":"2025","unstructured":"Gonzalez-Garcia LN, Restrepo CM, Llanes A et al (2025) Genetic diversity and comparative genomics across Leishmania (Viannia) species. Commun Biol 8:925. https:\/\/doi.org\/10.1038\/s42003-025-08331-1","journal-title":"Commun Biol"},{"key":"12801_CR23","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/life15101590","volume":"15","author":"A Llanes","year":"2025","unstructured":"Llanes A, Restrepo CM, Lleonart R (2025) Unraveling the genome diversity of Leishmania parasites using next-generation DNA sequencing strategies. Life 15:1590. https:\/\/doi.org\/10.3390\/life15101590","journal-title":"Life"},{"key":"12801_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3201\/eid3003.231160","volume":"30","author":"P Monsieurs","year":"2024","unstructured":"Monsieurs P et al (2024) Source tracing of Leishmania donovani in emerging foci of visceral leishmaniasis, western Nepal. Emerg Infect Dis 30:611\u2013620. https:\/\/doi.org\/10.3201\/eid3003.231160","journal-title":"Emerg Infect Dis"},{"key":"12801_CR25","doi-asserted-by":"publisher","first-page":"e0011920","DOI":"10.1371\/journal.pntd.0011920","volume":"18","author":"J S\u00e1dlov\u00e1","year":"2024","unstructured":"S\u00e1dlov\u00e1 J et al (2024) Comparative genomics of Leishmania donovani progeny from genetic crosses in two sand fly species and impact on the diversity of diagnostic and vaccine candidates. PLoS Negl Trop Dis 18:e0011920. https:\/\/doi.org\/10.1371\/journal.pntd.0011920","journal-title":"PLoS Negl Trop Dis"},{"key":"12801_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12864-025-11767-8","volume":"26","author":"JG Emond-Rheault","year":"2025","unstructured":"Emond-Rheault JG, Ferreira GR, Lavoie-Ouellet C, Smith MA, Papadopoulou B (2025) Novel insights into the Leishmania infantum transcriptome diversity of protein-coding and non-coding sequences in both stages of parasite development using nanopore direct RNA sequencing. BMC Genomics 26:573. https:\/\/doi.org\/10.1186\/s12864-025-11767-8","journal-title":"BMC Genomics"},{"key":"12801_CR27","doi-asserted-by":"publisher","first-page":"e0013108","DOI":"10.1371\/journal.pntd.0013108","volume":"19","author":"JE Martinez-Hernandez","year":"2025","unstructured":"Martinez-Hernandez JE, Aliaga-Tobar V, Gonz\u00e1lez-Rosales C, Monte-Neto R, Martin AJ, Maracaja-Coutinho V (2025) Comparative and systems analyses of Leishmania spp. non-coding RNAs through developmental stages. PLoS Negl Trop Dis 19:e0013108. https:\/\/doi.org\/10.1371\/journal.pntd.0013108","journal-title":"PLoS Negl Trop Dis"},{"key":"12801_CR28","doi-asserted-by":"publisher","first-page":"e2406776121","DOI":"10.1073\/pnas.2406776121","volume":"121","author":"CM Catta-Preta","year":"2024","unstructured":"Catta-Preta CM, Ghosh K, Sacks DL, Ferreira TR (2024) Single-cell atlas of Leishmania development in sand flies reveals the heterogeneity of transmitted parasites and their role in infection. Proc Natl Acad Sci U S A 121:e2406776121. https:\/\/doi.org\/10.1073\/pnas.2406776121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12801_CR29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/pathogens13100835","volume":"13","author":"MJ Moncada-Diaz","year":"2024","unstructured":"Moncada-Diaz MJ, Rodr\u00edguez-Almonacid CC, Quiceno-Giraldo E, Khuong FT, Muskus C, Karamysheva ZN (2024) Molecular mechanisms of drug resistance in Leishmania spp. Pathogens 13:835. https:\/\/doi.org\/10.3390\/pathogens13100835","journal-title":"Pathogens"},{"key":"12801_CR30","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.3390\/ijms25136903","volume":"25","author":"J M\u00fcller","year":"2024","unstructured":"M\u00fcller J et al (2024) Investigating antiprotozoal chemotherapies with novel proteomic tools\u2014chances and limitations: a critical review. Int J Mol Sci 25:6903. https:\/\/doi.org\/10.3390\/ijms25136903","journal-title":"Int J Mol Sci"},{"key":"12801_CR31","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1021\/acsinfecdis.4c00185","volume":"10","author":"L Tagliazucchi","year":"2024","unstructured":"Tagliazucchi L et al (2024) Deciphering host\u2013parasite interplay in Leishmania infection through a One Health view of proteomics studies on drug resistance. ACS Infect Dis 10:3202\u20133221. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00185","journal-title":"ACS Infect Dis"},{"key":"12801_CR32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/metabo14120658","volume":"14","author":"S Kim","year":"2024","unstructured":"Kim S, Ibarra-Meneses AV, Fernandez-Prada C, Huan T (2024) Global lipidomics reveals the lipid composition heterogeneity of extracellular vesicles from drug-resistant Leishmania. Metabolites 14:658. https:\/\/doi.org\/10.3390\/metabo14120658","journal-title":"Metabolites"},{"key":"12801_CR33","doi-asserted-by":"publisher","first-page":"e0011880","DOI":"10.1371\/journal.pntd.0011880","volume":"18","author":"JM Ribeiro","year":"2024","unstructured":"Ribeiro JM, Silva PA, Costa-Silva HM, Santi AMM, Murta SMF (2024) Deletion of the lipid droplet protein kinase gene affects lipid droplet biogenesis, parasite infectivity, and resistance to trivalent antimony in Leishmania infantum. PLoS Negl Trop Dis 18:e0011880. https:\/\/doi.org\/10.1371\/journal.pntd.0011880","journal-title":"PLoS Negl Trop Dis"},{"key":"12801_CR34","doi-asserted-by":"publisher","first-page":"e1012382","DOI":"10.1371\/journal.ppat.1012382","volume":"20","author":"LB Tulloch","year":"2024","unstructured":"Tulloch LB et al (2024) Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1. PLoS Pathog 20:e1012382. https:\/\/doi.org\/10.1371\/journal.ppat.1012382","journal-title":"PLoS Pathog"},{"key":"12801_CR35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/pathogens11080950","volume":"11","author":"M Soni","year":"2022","unstructured":"Soni M, Pratap JV (2022) Development of novel anti-leishmanials: the case for structure-based approaches. Pathogens 11:950. https:\/\/doi.org\/10.3390\/pathogens11080950","journal-title":"Pathogens"},{"key":"12801_CR36","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.pt.2024.06.003","volume":"40","author":"S Aellig","year":"2024","unstructured":"Aellig S et al (2024) LeishGEM: genome-wide deletion mutant fitness and protein localisations in Leishmania. Trends Parasitol 40:675\u2013678. https:\/\/doi.org\/10.1016\/j.pt.2024.06.003","journal-title":"Trends Parasitol"},{"key":"12801_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1021\/acsinfecdis.8b00226","volume":"5","author":"V Corpas-Lopez","year":"2019","unstructured":"Corpas-Lopez V et al (2019) Pharmacological validation of N-myristoyltransferase as a drug target in Leishmania donovani. ACS Infect Dis 5:111\u2013122. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00226","journal-title":"ACS Infect Dis"},{"key":"12801_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.biochi.2019.08.015","volume":"166","author":"JS Grewal","year":"2019","unstructured":"Grewal JS, Catta-Preta CM, Brown E, Anand J, Mottram JC (2019) Evaluation of clan CD C11 peptidase PNT1 and other Leishmania mexicana cysteine peptidases as potential drug targets. Biochimie 166:150\u2013160. https:\/\/doi.org\/10.1016\/j.biochi.2019.08.015","journal-title":"Biochimie"},{"key":"12801_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00203-024-04118-w","volume":"206","author":"D Saha","year":"2024","unstructured":"Saha D, Jha AN (2024) Integrated subtractive genomics and structure-based approach to unravel the therapeutic drug target of Leishmania species. Arch Microbiol 206:408. https:\/\/doi.org\/10.1007\/s00203-024-04118-w","journal-title":"Arch Microbiol"},{"key":"12801_CR40","doi-asserted-by":"publisher","first-page":"e70309","DOI":"10.1002\/jbt.70309","volume":"39","author":"B Mor","year":"2025","unstructured":"Mor B, Tokal\u0131 FS, Y\u0131ld\u0131z B, \u015eenol H, Aksu \u015e, Mor N (2025) Design, synthesis, and evaluation of novel quinazolin-4(3H)-one derivatives: anti-leishmanial activity, selectivity, and molecular docking insights. J Biochem Mol Toxicol 39:e70309. https:\/\/doi.org\/10.1002\/jbt.70309","journal-title":"J Biochem Mol Toxicol"},{"key":"12801_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.biochi.2025.03.007","volume":"234","author":"G Dias-Lopes","year":"2025","unstructured":"Dias-Lopes G, Cruz SMX, Pereira BAS, Zabala-Pe\u00f1afiel A, Alves CR (2025) Molecular and biochemical approaches of the trypanothione system in Leishmania spp.: a key player in parasite resistance to antimonial therapy. Biochimie 234:40\u201347. https:\/\/doi.org\/10.1016\/j.biochi.2025.03.007","journal-title":"Biochimie"},{"key":"12801_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/molecules28010338","volume":"28","author":"VN Madia","year":"2023","unstructured":"Madia VN et al (2023) Inhibition of Leishmania infantum trypanothione reductase by new aminopropanone derivatives interacting with the NADPH binding site. Molecules 28:338. https:\/\/doi.org\/10.3390\/molecules28010338","journal-title":"Molecules"},{"key":"12801_CR43","doi-asserted-by":"publisher","first-page":"114675","DOI":"10.1016\/j.ejmech.2022.114675","volume":"243","author":"M Alcon-Calderon","year":"2022","unstructured":"Alcon-Calderon M et al (2022) Identification of Leishmania infantum trypanothione synthetase inhibitors with leishmanicidal activity from a non-biased in-house chemical library. Eur J Med Chem 243:114675. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114675","journal-title":"Eur J Med Chem"},{"key":"12801_CR44","doi-asserted-by":"publisher","first-page":"106392","DOI":"10.1016\/j.actatropica.2022.106392","volume":"230","author":"M Nateghi-Rostami","year":"2022","unstructured":"Nateghi-Rostami M, Tasbihi M, Darzi F (2022) Involvement of tryparedoxin peroxidase (TryP) and trypanothione reductase (TryR) in antimony unresponsiveness of Leishmania tropica clinical isolates from Iran. Acta Trop 230:106392. https:\/\/doi.org\/10.1016\/j.actatropica.2022.106392","journal-title":"Acta Trop"},{"key":"12801_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s13071-024-06562-5","volume":"17","author":"IFM Santos","year":"2024","unstructured":"Santos IFM, Moreira DS, Costa KF, Ribeiro JM, Murta SMF, Santi AMM (2024) Ascorbate peroxidase modulation confirms a key role in Leishmania infantum oxidative defence. Parasit Vectors 17:472. https:\/\/doi.org\/10.1186\/s13071-024-06562-5","journal-title":"Parasit Vectors"},{"key":"12801_CR46","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.1080\/07391102.2023.2256879","volume":"42","author":"H Khan","year":"2024","unstructured":"Khan H et al (2024) Investigating the role of Sterol C24-Methyl transferase mutation on drug resistance in leishmaniasis and identifying potential inhibitors. J Biomol Struct Dyn 42:10374\u201310387. https:\/\/doi.org\/10.1080\/07391102.2023.2256879","journal-title":"J Biomol Struct Dyn"},{"key":"12801_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/omi.2014.0163","volume":"19","author":"MD Jamdhade","year":"2015","unstructured":"Jamdhade MD et al (2015) Comprehensive proteomics analysis of glycosomes from Leishmania donovani. OMICS 19:157\u2013170. https:\/\/doi.org\/10.1089\/omi.2014.0163","journal-title":"OMICS"},{"key":"12801_CR48","doi-asserted-by":"publisher","unstructured":"Sharma VK, Garg P, Gupta P (2025) Pharmacoinformatics-based identification of dual inhibitors of leishmanial DHFR and PTR1 enzymes. https:\/\/doi.org\/10.1016\/j.lddd.2025.100197. Lett Drug Des Discov","DOI":"10.1016\/j.lddd.2025.100197"},{"key":"12801_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/tropicalmed9020041","volume":"9","author":"HL Barazorda-Ccahuana","year":"2024","unstructured":"Barazorda-Ccahuana HL et al (2024) Targeting with structural analogs of natural products the purine salvage pathway in Leishmania (Leishmania) infantum by computer-aided drug-design approaches. Trop Med Infect Dis 9:41. https:\/\/doi.org\/10.3390\/tropicalmed9020041","journal-title":"Trop Med Infect Dis"},{"key":"12801_CR50","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1002\/jcb.70060","volume":"126","author":"EM Barreto","year":"2025","unstructured":"Barreto EM et al (2025) Unveiling novel arginase inhibitors for cutaneous leishmaniasis using drug repurposing and virtual screening approaches. J Cell Biochem 126:e70060. https:\/\/doi.org\/10.1002\/jcb.70060","journal-title":"J Cell Biochem"},{"key":"12801_CR51","doi-asserted-by":"publisher","first-page":"111619","DOI":"10.1016\/j.molbiopara.2024.111619","volume":"258","author":"RJ Burge","year":"2024","unstructured":"Burge RJ, Jameson KH, Geoghegan V, Dowle AA, Mottram JC, Wilkinson AJ (2024) Formation of functional E3 ligase complexes with UBC2 and UEV1 of Leishmania mexicana. Mol Biochem Parasitol 258:111619. https:\/\/doi.org\/10.1016\/j.molbiopara.2024.111619","journal-title":"Mol Biochem Parasitol"},{"key":"12801_CR52","doi-asserted-by":"publisher","first-page":"e1008455","DOI":"10.1371\/journal.ppat.1008455","volume":"16","author":"A Damianou","year":"2020","unstructured":"Damianou A et al (2020) Essential roles for deubiquitination in Leishmania life cycle progression. PLoS Pathog 16:e1008455. https:\/\/doi.org\/10.1371\/journal.ppat.1008455","journal-title":"PLoS Pathog"},{"key":"12801_CR53","doi-asserted-by":"publisher","first-page":"e00559","DOI":"10.1128\/IAI.00559-20","volume":"89","author":"P Prasanna","year":"2021","unstructured":"Prasanna P, Upadhyay A (2021) Heat shock proteins as the druggable targets in leishmaniasis: promises and perils. Infect Immun 89:e00559\u2013e00520. https:\/\/doi.org\/10.1128\/IAI.00559-20","journal-title":"Infect Immun"},{"key":"12801_CR54","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41467-017-01664-4","volume":"8","author":"M Shalev-Benami","year":"2017","unstructured":"Shalev-Benami M et al (2017) Atomic resolution snapshot of Leishmania ribosome inhibition by the aminoglycoside paromomycin. Nat Commun 8:1589. https:\/\/doi.org\/10.1038\/s41467-017-01664-4","journal-title":"Nat Commun"},{"key":"12801_CR55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/AAC.00506-10","volume":"55","author":"MM Fern\u00e1ndez","year":"2011","unstructured":"Fern\u00e1ndez MM, Malchiodi EL, Algranati ID (2011) Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother 55:86\u201393. https:\/\/doi.org\/10.1128\/AAC.00506-10","journal-title":"Antimicrob Agents Chemother"},{"key":"12801_CR56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/microorganisms9040691","volume":"9","author":"A Efstathiou","year":"2021","unstructured":"Efstathiou A, Smirlis D (2021) Leishmania protein kinases: important regulators of the parasite life cycle and molecular targets for treating leishmaniasis. Microorganisms 9:691. https:\/\/doi.org\/10.3390\/microorganisms9040691","journal-title":"Microorganisms"},{"key":"12801_CR57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","volume":"560","author":"S Wyllie","year":"2018","unstructured":"Wyllie S et al (2018) Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 560:192\u2013197. https:\/\/doi.org\/10.1038\/s41586-018-0356-z","journal-title":"Nature"},{"key":"12801_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/1756-3305-7-234","volume":"7","author":"A Efstathiou","year":"2014","unstructured":"Efstathiou A et al (2014) An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial glycogen synthase kinase-3 over leishmanial cdc2-related protein kinase 3. Parasit Vectors 7:234. https:\/\/doi.org\/10.1186\/1756-3305-7-234","journal-title":"Parasit Vectors"},{"key":"12801_CR59","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41467-021-21360-8","volume":"12","author":"N Baker","year":"2021","unstructured":"Baker N et al (2021) Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival. Nat Commun 12:1244. https:\/\/doi.org\/10.1038\/s41467-021-21360-8","journal-title":"Nat Commun"},{"key":"12801_CR60","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s44319-024-00084-y","volume":"25","author":"E Myburgh","year":"2024","unstructured":"Myburgh E et al (2024) TORC1 is an essential regulator of nutrient-controlled proliferation and differentiation in Leishmania. EMBO Rep 25:1075\u20131105. https:\/\/doi.org\/10.1038\/s44319-024-00084-y","journal-title":"EMBO Rep"},{"key":"12801_CR61","doi-asserted-by":"publisher","first-page":"RP97437","DOI":"10.7554\/eLife.97437","volume":"13","author":"NH May","year":"2025","unstructured":"May NH et al (2025) Improved base editing and functional screening in Leishmania via co-expression of the AsCas12a ultra variant, a T7 RNA polymerase, and a cytosine base editor. eLife 13:RP97437. https:\/\/doi.org\/10.7554\/eLife.97437","journal-title":"eLife"},{"key":"12801_CR62","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1128\/AAC.02022-13","volume":"58","author":"N Rachidi","year":"2014","unstructured":"Rachidi N et al (2014) Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. Antimicrob Agents Chemother 58:1501\u20131515. https:\/\/doi.org\/10.1128\/AAC.02022-13","journal-title":"Antimicrob Agents Chemother"},{"key":"12801_CR63","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.ijpara.2007.04.008","volume":"37","author":"M Wiese","year":"2007","unstructured":"Wiese M (2007) Leishmania MAP kinases\u2014familiar proteins in an unusual context. Int J Parasitol 37:1053\u20131062. https:\/\/doi.org\/10.1016\/j.ijpara.2007.04.008","journal-title":"Int J Parasitol"},{"key":"12801_CR64","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1016\/j.ejmech.2010.09.020","volume":"45","author":"P Saravanan","year":"2010","unstructured":"Saravanan P, Venkatesan SK, Mohan CG, Patra S, Dubey VK (2010) Mitogen-activated protein kinase 4 of Leishmania parasite as a therapeutic target. Eur J Med Chem 45:5662\u20135670. https:\/\/doi.org\/10.1016\/j.ejmech.2010.09.020","journal-title":"Eur J Med Chem"},{"key":"12801_CR65","doi-asserted-by":"publisher","first-page":"e1004347","DOI":"10.1371\/journal.ppat.1004347","volume":"10","author":"M Cayla","year":"2014","unstructured":"Cayla M et al (2014) Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability. PLoS Pathog 10:e1004347. https:\/\/doi.org\/10.1371\/journal.ppat.1004347","journal-title":"PLoS Pathog"},{"key":"12801_CR66","doi-asserted-by":"publisher","first-page":"103086","DOI":"10.1016\/j.ceca.2025.103086","volume":"124","author":"NCC Coelho","year":"2025","unstructured":"Coelho NCC, Vel\u00e1squez AMA, De Lima JS, Ramos ALD, Cilli EM, Graminha MA (2025) Calcium homeostasis in trypanosomatids: a review of molecular targets and inhibitors. Cell Calcium 124:103086. https:\/\/doi.org\/10.1016\/j.ceca.2025.103086","journal-title":"Cell Calcium"},{"key":"12801_CR67","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pt.2019.12.010","volume":"36","author":"MF Laranjeira-Silva","year":"2020","unstructured":"Laranjeira-Silva MF, Hamza I, P\u00e9rez-Victoria JM (2020) Iron and heme metabolism at the Leishmania\u2013host interface. Trends Parasitol 36:279\u2013289. https:\/\/doi.org\/10.1016\/j.pt.2019.12.010","journal-title":"Trends Parasitol"},{"key":"12801_CR68","doi-asserted-by":"publisher","first-page":"e1013993","DOI":"10.1371\/journal.ppat.1013993","volume":"22","author":"G Juez-Castillo","year":"2026","unstructured":"Juez-Castillo G et al (2026) Heme limitation induces LHR2, an essential gene for Leishmania pathogenesis. PLoS Pathog 22:e1013993. https:\/\/doi.org\/10.1371\/journal.ppat.1013993","journal-title":"PLoS Pathog"},{"key":"12801_CR69","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1021\/acsinfecdis.9b00426","volume":"6","author":"RJ Wall","year":"2020","unstructured":"Wall RJ et al (2020) The Qi site of cytochrome b is a promiscuous drug target in Trypanosoma cruzi and Leishmania donovani. ACS Infect Dis 6:515\u2013528. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00426","journal-title":"ACS Infect Dis"},{"key":"12801_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biochi.2022.11.015","volume":"207","author":"N Devsani","year":"2023","unstructured":"Devsani N, Vemula D, Bhandari V (2023) The glycoprotein gp63\u2014a potential pan drug target for developing new antileishmanial agents. Biochimie 207:75\u201382. https:\/\/doi.org\/10.1016\/j.biochi.2022.11.015","journal-title":"Biochimie"},{"key":"12801_CR71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00894-026-06647-1","volume":"32","author":"V Gouri","year":"2026","unstructured":"Gouri V, Kanojia A, Kumar A, Samant M (2026) Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis. J Mol Model 32:68. https:\/\/doi.org\/10.1007\/s00894-026-06647-1","journal-title":"J Mol Model"},{"key":"12801_CR72","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/cmi.12456","volume":"17","author":"L Sollelis","year":"2015","unstructured":"Sollelis L, Ghorbal M, MacPherson CR et al (2015) First efficient CRISPR-Cas9-mediated genome editing in Leishmania parasites. Cell Microbiol 17:1405\u20131412. https:\/\/doi.org\/10.1111\/cmi.12456","journal-title":"Cell Microbiol"},{"key":"12801_CR73","doi-asserted-by":"publisher","first-page":"170095","DOI":"10.1098\/rsos.170095","volume":"4","author":"T Beneke","year":"2017","unstructured":"Beneke T, Madden R, Makin L, Valli J, Sunter J, Gluenz E (2017) A CRISPR-Cas9 high-throughput genome editing toolkit for kinetoplastids. R Soc Open Sci 4:170095. https:\/\/doi.org\/10.1098\/rsos.170095","journal-title":"R Soc Open Sci"},{"key":"12801_CR74","doi-asserted-by":"publisher","first-page":"e01788","DOI":"10.1128\/mBio.01788-17","volume":"8","author":"LC Soares Medeiros","year":"2017","unstructured":"Soares Medeiros LC et al (2017) Rapid, selection-free, high-efficiency genome editing in protozoan parasites using CRISPR-Cas9 ribonucleoproteins. mBio 8:e01788\u2013e01717. https:\/\/doi.org\/10.1128\/mBio.01788-17","journal-title":"mBio"},{"key":"12801_CR75","doi-asserted-by":"publisher","first-page":"1788564","DOI":"10.3389\/fcimb.2026.1788564","volume":"16","author":"C McNiven","year":"2026","unstructured":"McNiven C, Trindade JBC, Geoghegan V, Faria JR, Mottram JC (2026) CRISPR-Cas9 precision editing of kinetochore protein phosphosite codons in Leishmania mexicana. Front Cell Infect Microbiol 16:1788564. https:\/\/doi.org\/10.3389\/fcimb.2026.1788564","journal-title":"Front Cell Infect Microbiol"},{"key":"12801_CR76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41467-024-55538-7","volume":"16","author":"A Albuquerque-Wendt","year":"2025","unstructured":"Albuquerque-Wendt A et al (2025) TransLeish: identification of membrane transporters essential for survival of intracellular Leishmania parasites in a systematic gene deletion screen. Nat Commun 16:299. https:\/\/doi.org\/10.1038\/s41467-024-55538-7","journal-title":"Nat Commun"},{"key":"12801_CR77","doi-asserted-by":"publisher","first-page":"e0316331","DOI":"10.1371\/journal.pone.0316331","volume":"19","author":"WW Zhang","year":"2024","unstructured":"Zhang WW, Matlashewski G (2024) Evidence for gene essentiality in Leishmania using CRISPR. PLoS ONE 19:e0316331. https:\/\/doi.org\/10.1371\/journal.pone.0316331","journal-title":"PLoS ONE"},{"key":"12801_CR78","doi-asserted-by":"publisher","first-page":"e00861","DOI":"10.1128\/mBio.00861-15","volume":"6","author":"WW Zhang","year":"2015","unstructured":"Zhang WW, Matlashewski G (2015) CRISPR-Cas9-mediated genome editing in Leishmania donovani. mBio 6:e00861\u2013e00815. https:\/\/doi.org\/10.1128\/mBio.00861-15","journal-title":"mBio"},{"key":"12801_CR79","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1093\/jac\/dkz334","volume":"74","author":"B Vergnes","year":"2019","unstructured":"Vergnes B et al (2019) A single amino acid substitution (H451Y) in Leishmania calcium-dependent kinase SCAMK confers high tolerance and resistance to antimony. J Antimicrob Chemother 74:3231\u20133239. https:\/\/doi.org\/10.1093\/jac\/dkz334","journal-title":"J Antimicrob Chemother"},{"key":"12801_CR80","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1038\/s41467-019-13344-6","volume":"10","author":"A Bhattacharya","year":"2019","unstructured":"Bhattacharya A et al (2019) Coupling chemical mutagenesis to next-generation sequencing for the identification of drug resistance mutations in Leishmania. Nat Commun 10:5627. https:\/\/doi.org\/10.1038\/s41467-019-13344-6","journal-title":"Nat Commun"},{"key":"12801_CR81","doi-asserted-by":"publisher","first-page":"104378","DOI":"10.1016\/j.ebiom.2022.104378","volume":"86","author":"JBT Carnielli","year":"2022","unstructured":"Carnielli JBT et al (2022) 3\u2032 Nucleotidase\/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine. EBioMedicine 86:104378. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104378","journal-title":"EBioMedicine"},{"key":"12801_CR82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00430-025-00827-1","volume":"214","author":"F Darzi","year":"2025","unstructured":"Darzi F, Khamesipour A, Tasbihi M, Bahraminasab M, Nateghi-Rostami M (2025) CRISPR\/Cas9-mediated deletion of a kinetoplast-associated gene attenuates virulence in Leishmania major parasites. Med Microbiol Immunol 214:16. https:\/\/doi.org\/10.1007\/s00430-025-00827-1","journal-title":"Med Microbiol Immunol"},{"key":"12801_CR83","doi-asserted-by":"publisher","first-page":"e23367","DOI":"10.1096\/fj.202301665R","volume":"38","author":"N Baron","year":"2024","unstructured":"Baron N, Purushotham R, Pullaiahgari D, Bose P, Zarivach R, Shapira M (2024) LeishIF4E2 is a cap-binding protein that plays a role in Leishmania cell cycle progression. FASEB J 38:e23367. https:\/\/doi.org\/10.1096\/fj.202301665R","journal-title":"FASEB J"},{"key":"12801_CR84","doi-asserted-by":"publisher","first-page":"e1014194","DOI":"10.1371\/journal.ppat.1014194","volume":"22","author":"JBT Carnielli","year":"2026","unstructured":"Carnielli JBT, Brannigan JA, Ramos PZ, Jones NG, Cou\u00f1ago RM, Sj\u00f6 P, Lima APCA, Wilkinson AJ, Mottram JC (2026) Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression. PLoS Pathog 22:e1014194. https:\/\/doi.org\/10.1371\/journal.ppat.1014194","journal-title":"PLoS Pathog"},{"key":"12801_CR85","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.micpath.2021.105281","volume":"161","author":"S Ebrahimi","year":"2021","unstructured":"Ebrahimi S, Kalantari M, Alipour H, Azizi K, Asgari Q, Bahreini MS (2021) In vitro evaluation of CRISPR PX-LmGP63 vector effect on pathogenicity of Leishmania major as a primary step to control leishmaniasis. Microb Pathog 161:105281. https:\/\/doi.org\/10.1016\/j.micpath.2021.105281","journal-title":"Microb Pathog"},{"key":"12801_CR86","doi-asserted-by":"publisher","first-page":"e01941","DOI":"10.1128\/mBio.01941-19","volume":"10","author":"I Louradour","year":"2019","unstructured":"Louradour I, Ghosh K, Inbar E, Sacks DL (2019) CRISPR\/Cas9 mutagenesis in Phlebotomus papatasi: the immune deficiency pathway impacts vector competence for Leishmania major. mBio 10:e01941\u2013e01919. https:\/\/doi.org\/10.1128\/mBio.01941-19","journal-title":"mBio"},{"key":"12801_CR87","doi-asserted-by":"publisher","first-page":"e1008828","DOI":"10.1371\/journal.pgen.1008828","volume":"16","author":"JD Damasceno","year":"2020","unstructured":"Damasceno JD et al (2020) Conditional knockout of RAD51-related genes in Leishmania major reveals a critical role for homologous recombination during genome replication. PLoS Genet 16:e1008828. https:\/\/doi.org\/10.1371\/journal.pgen.1008828","journal-title":"PLoS Genet"},{"key":"12801_CR88","doi-asserted-by":"publisher","first-page":"e13159","DOI":"10.1111\/cmi.13159","volume":"22","author":"A Yagoubat","year":"2020","unstructured":"Yagoubat A et al (2020) Universal highly efficient conditional knockout system in Leishmania, with a focus on untranslated region preservation. Cell Microbiol 22:e13159. https:\/\/doi.org\/10.1111\/cmi.13159","journal-title":"Cell Microbiol"},{"key":"12801_CR89","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ijpddr.2025.100629","volume":"29","author":"M Queffeulou","year":"2025","unstructured":"Queffeulou M et al (2025) CRISPR-Cas13b-mediated gene knockdowns in Leishmania infantum. Int J Parasitol Drugs Drug Resist 29:100629. https:\/\/doi.org\/10.1016\/j.ijpddr.2025.100629","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"12801_CR90","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1021\/acs.jcim.5c02947","volume":"66","author":"VAF Costa","year":"2026","unstructured":"Costa VAF et al (2026) Multiscale-aware graph embedding approach uncovers LC-61, a potent anti-Leishmania infantum compound. J Chem Inf Model 66:3643\u20133659. https:\/\/doi.org\/10.1021\/acs.jcim.5c02947","journal-title":"J Chem Inf Model"},{"key":"12801_CR91","doi-asserted-by":"publisher","first-page":"e01979","DOI":"10.1002\/slct.202501979","volume":"10","author":"L Salvador do Amaral","year":"2025","unstructured":"Salvador do Amaral L et al (2025) Integration of machine learning-QSAR and polypharmacology in drug discovery for leishmaniasis using natural and repurposed compounds. ChemistrySelect 10:e01979. https:\/\/doi.org\/10.1002\/slct.202501979","journal-title":"ChemistrySelect"},{"key":"12801_CR92","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00203-026-04989-1","volume":"208","author":"L Mariano-Fernandes","year":"2026","unstructured":"Mariano-Fernandes L, Silva J, da Rocha MN, Marinho MM, Marinho ES (2026) Targeting of Leishmania proteins by \u03b2-lapachone derivatives reveals a promising multitarget candidate. Arch Microbiol 208:428. https:\/\/doi.org\/10.1007\/s00203-026-04989-1","journal-title":"Arch Microbiol"},{"key":"12801_CR93","doi-asserted-by":"publisher","first-page":"837460","DOI":"10.3389\/fitd.2022.837460","volume":"3","author":"GJ Wijnant","year":"2022","unstructured":"Wijnant GJ et al (2022) Tackling drug resistance and other causes of treatment failure in leishmaniasis. Front Trop Dis 3:837460. https:\/\/doi.org\/10.3389\/fitd.2022.837460","journal-title":"Front Trop Dis"},{"key":"12801_CR94","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00281-020-00788-y","volume":"42","author":"PM Kaye","year":"2020","unstructured":"Kaye PM, Cruz I, Picado A, Van Bocxlaer K, Croft SL (2020) Leishmaniasis immunopathology: impact on design and use of vaccines, diagnostics and drugs. Semin Immunopathol 42:247\u2013264. https:\/\/doi.org\/10.1007\/s00281-020-00788-y","journal-title":"Semin Immunopathol"},{"key":"12801_CR95","doi-asserted-by":"publisher","first-page":"113097","DOI":"10.1016\/j.celrep.2023.113097","volume":"42","author":"K Karagiannis","year":"2023","unstructured":"Karagiannis K et al (2023) Dual-scRNA-seq analysis reveals rare and uncommon parasitized cell populations in chronic L. donovani infection. Cell Rep 42:113097. https:\/\/doi.org\/10.1016\/j.celrep.2023.113097","journal-title":"Cell Rep"},{"key":"12801_CR96","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13071-026-07361-w","volume":"19","author":"FR Li","year":"2026","unstructured":"Li FR et al (2026) Single-cell transcriptomics reveals lipid metabolism reprogramming in macrophages in vitro during early stages of Leishmania donovani infection. Parasit Vectors 19:176. https:\/\/doi.org\/10.1186\/s13071-026-07361-w","journal-title":"Parasit Vectors"},{"key":"12801_CR97","doi-asserted-by":"publisher","first-page":"1870524","DOI":"10.3389\/fimmu.2026.1870524","volume":"17","author":"NS Dey","year":"2026","unstructured":"Dey NS et al (2026) Spatial mapping of Ethiopian cutaneous leishmaniasis lesions reveals distinct tissue level immune programs. Front Immunol 17:1870524. https:\/\/doi.org\/10.3389\/fimmu.2026.1870524","journal-title":"Front Immunol"},{"key":"12801_CR98","doi-asserted-by":"publisher","first-page":"104518","DOI":"10.1016\/j.drudis.2025.104518","volume":"30","author":"J Delile","year":"2025","unstructured":"Delile J, Mukherjee S, Mueller J, Khalil I, Zhukov L, Meier C (2025) Foundation models in drug discovery: phenomenal growth today, transformative potential tomorrow. Drug Discov Today 30:104518. https:\/\/doi.org\/10.1016\/j.drudis.2025.104518","journal-title":"Drug Discov Today"},{"key":"12801_CR99","doi-asserted-by":"publisher","first-page":"104617","DOI":"10.1016\/j.drudis.2026.104617","volume":"31","author":"SP Venkatapurapu","year":"2026","unstructured":"Venkatapurapu SP et al (2026) Digital twins for accelerating drug discovery and development: opportunities and challenges. Drug Discov Today 31:104617. https:\/\/doi.org\/10.1016\/j.drudis.2026.104617","journal-title":"Drug Discov Today"},{"key":"12801_CR100","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41746-025-01447-y","volume":"8","author":"K Sel","year":"2025","unstructured":"Sel K et al (2025) Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine. NPJ Digit Med 8:40. https:\/\/doi.org\/10.1038\/s41746-025-01447-y","journal-title":"NPJ Digit Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12801-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:03:06Z","timestamp":1790254986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12801"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12801-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI) to improve the readability and language of this manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics and Consent to Participate Declarations","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1620"}}